Abstract
We report a case of heparin-induced thrombocytopenia with thrombosis type 2 (HITT 2) that was first complicated by intracerebral hemorrhage (ICH) and later by deep venous thrombosis (DVT). HITT 2 was initially managed conventionally with argatroban, which was stopped when ICH was discovered. The size of ICH increased despite attempts to increase platelet count by platelet transfusions. At this point of the clinical dilemma, plasma exchange was utilized effectively to recover the platelet count and deter ICH progression. The clinical course was later complicated by DVT, for which fondaparinux was given. This case represents a rare clinical scenario of HITT 2 resulting in progressive ICH that excluded the use of antithrombotic agents as part of HITT therapy. We believe that the use of plasmapheresis as a salvage procedure in such situations is effective and life-saving. Physicians should be aware of plasmapheresis as a therapeutic option in HITT 2 in cases in which anticoagulation is contraindicated.
This is a preview of subscription content, log in via an institution to check access.
References
Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106:2710–5.
Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–5.
Harbrecht U, Bastians B, Kredteck A, et al. Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin. Neurology. 2004;62:657–9.
Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101:2955–9.
Morris TA, Castrejon S, Devendra G, Gamst AC. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis. Chest. 2007;132:1131–9.
Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108:2937–41.
Rosenberger LH, Smith PW, Sawyer RG, et al. Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. Crit Care Med. 2011;39:833–8.
Hertle DN, Hahnel S, Richter GM, et al. The use of danaparoid to manage coagulopathy in a neurosurgical patient with heparin-induced thrombocytopenia type II and intracerebral haemorrhage. Br J Neurosurg. 2011;25:117–9.
Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121:535–55.
Kurtz LE, Yang S. Bilateral adrenal hemorrhage associated with heparin induced thrombocytopenia. Am J Hematol. 2007;82:493–4.
Namias N. Chance favors the prepared mind: the association between heparin-induced thrombocytopenia and bilateral adrenal hemorrhage. Crit Care Med. 2011;39:912–3.
Tsai HC, Yen HC, Hsu JC, Lin CL. Heparin-induced thrombocytopenia associated with intra-tumour haemorrhage in cavernous sinus after cardiac myxoma surgery. Br J Neurosurg. 2009;23:95–6.
Wester JP, Haas FJ, Biesma DH, et al. Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients. Intensive Care Med. 2004;30:1927–34.
Pohl C, Harbrecht U, Greinacher A, et al. Neurologic complications in immune-mediated heparin-induced thrombocytopenia. Neurology. 2000;54:1240–5.
Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion. 2008;48:2128–32.
Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood. 2003;101:3049–51.
Bouvier JL, Lefevre P, Villain P, et al. Treatment of serious heparin-induced thrombocytopenia by plasma exchange: report on 4 cases. Thromb Res. 1988;51:335–6.
Kajitani M, Aguinaga M, Johnson CE, et al. Use of plasma exchange and heparin during cardiopulmonary bypass for a patient with heparin induced thrombocytopenia: a case report. J Card Surg. 2001;16:313–8.
Voeller RK, Melby SJ, Grizzell BE, Moazami N. Novel use of plasmapheresis in a patient with heparin-induced thrombocytopenia requiring urgent insertion of a left ventricular assist device under cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2010;140:e56–8.
Welsby IJ, Um J, Milano CA, et al. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg. 2010;110:30–5.
Kramer R, Oberg-Higgins P, Russo L, Braxton JH. Heparin-induced thrombocytopenia with thrombosis syndrome managed with plasmapheresis. Interact Cardiovasc Thorac Surg. 2009;8:439–41.
Poullin P, Pietri PA, Lefevre P. Heparin-induced thrombocytopenia with thrombosis: successful treatment with plasma exchange. Br J Haematol. 1998;102:630–1.
Antonijevic NM, Savic NB, Perunicic J, et al. Salvage late plasmapheresis in a patient with pulmonary embolism caused by heparin-induced thrombocytopenia primarily resistant to danaparoid sodium and lepirudin. J Clin Apher. 2006;21:252–5.
Robinson JA, Lewis BE. Plasmapheresis in the management of heparin-induced thrombocytopenia. Semin Hematol. 1999;36:29–32.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tun, N.M., Bo, Z.M., Ahluwalia, M. et al. A rare case of intracerebral hemorrhage complicating heparin-induced thrombocytopenia with thrombosis: a clinical dilemma ameliorated by novel use of plasmapheresis. Int J Hematol 96, 513–515 (2012). https://doi.org/10.1007/s12185-012-1161-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-012-1161-3